BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, McNally P, Ramsey BW, Rayment JH, Rowe SM, Tullis E, Ahluwalia N, Chu C, Ho T, Moskowitz SM, Noel S, Tian S, Waltz D, Weinstock TG, Xuan F, Wainwright CE, McColley SA. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. Am J Respir Crit Care Med 2021;203:1522-32. [PMID: 33734030 DOI: 10.1164/rccm.202102-0509OC] [Cited by in Crossref: 57] [Cited by in F6Publishing: 63] [Article Influence: 57.0] [Reference Citation Analysis]
Number Citing Articles
1 Gifford AH, Taylor-cousar JL, Davies JC, Mcnally P. Update on Clinical Outcomes of Highly Effective Modulator Therapy. Clinics in Chest Medicine 2022;43:677-695. [DOI: 10.1016/j.ccm.2022.06.009] [Reference Citation Analysis]
2 de Melo ACV, de Souza KSC, da Silva HPV, Maia JMDC, Dantas VM, Bezerra JF, de Rezende AA. Screening by high‐throughput sequencing for pathogenic variants in cystic fibrosis: Benefit of introducing personalized therapies. J Cellular Molecular Medi 2022. [DOI: 10.1111/jcmm.17605] [Reference Citation Analysis]
3 Bowerman C, Ratjen F, Stanojevic S. Estimating the minimum sample size for interventional and observational studies using the lung clearance index as an endpoint✰. Journal of Cystic Fibrosis 2022. [DOI: 10.1016/j.jcf.2022.11.003] [Reference Citation Analysis]
4 Goralski JL, Chung SH, Ceppe AS, Powell MZ, Sakthivel M, Handly BD, Lee YZ, Donaldson SH. Dynamic Perfluorinated Gas MRI Shows Improved Lung Ventilation in People with Cystic Fibrosis after Elexacaftor/Tezacaftor/Ivacaftor: An Observational Study. JCM 2022;11:6160. [DOI: 10.3390/jcm11206160] [Reference Citation Analysis]
5 Kazmerski TM, Stransky OM, Lavage DR, Taylor-cousar JL, Sawicki GS, Ladores SL, Godfrey EM, Aitken ML, Fields A, Sufian S, Jain M, Barto TL, Billings J, Hadjiliadis D, Jain R. Sexual and reproductive health experiences and care of adult women with cystic fibrosis. Journal of Cystic Fibrosis 2022. [DOI: 10.1016/j.jcf.2022.09.013] [Reference Citation Analysis]
6 Southern KW, Castellani C, Lammertyn E, Smyth A, Vandevanter D, van Koningsbruggen-rietschel S, Barben J, Bevan A, Brokaar E, Collins S, Connett GJ, Daniels TW, Davies J, Declercq D, Gartner S, Gramegna A, Hamilton N, Hauser J, Kashirskaya N, Kessler L, Lowdon J, Makukh H, Martin C, Morrison L, Nazareth D, Noordhoek J, O'neill C, Owen E, Oxley H, Raraigh KS, Raynal C, Robinson K, Roehmel J, Schwarz C, Sermet I, Shteinberg M, Sinha I, Takawira C, van Mourik P, Verkleij M, Waller MD, Duff A. Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis. Journal of Cystic Fibrosis 2022. [DOI: 10.1016/j.jcf.2022.10.002] [Reference Citation Analysis]
7 Castellani C, De Boeck K, De Wachter E, Sermet-gaudelus I, Simmonds N, Southern K. ECFS standards of care on CFTR-related disorders: Updated diagnostic criteria. Journal of Cystic Fibrosis 2022. [DOI: 10.1016/j.jcf.2022.09.011] [Reference Citation Analysis]
8 Pallenberg ST, Pust MM, Rosenboom I, Hansen G, Wiehlmann L, Dittrich AM, Tümmler B. Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome. Microbiol Spectr 2022;:e0145422. [PMID: 36154176 DOI: 10.1128/spectrum.01454-22] [Reference Citation Analysis]
9 Caverly LJ. Considerations for CF airway infection sampling and impact of CFTR modulators. J Cyst Fibros 2022:S1569-1993(22)00681-6. [PMID: 36153229 DOI: 10.1016/j.jcf.2022.09.004] [Reference Citation Analysis]
10 Dawood SN, Rabih AM, Niaj A, Raman A, Uprety M, Calero MJ, Villanueva MRB, Joshaghani N, Villa N, Badla O, Goit R, Saddik SE, Mohammed L. Newly Discovered Cutting-Edge Triple Combination Cystic Fibrosis Therapy: A Systematic Review. Cureus 2022. [DOI: 10.7759/cureus.29359] [Reference Citation Analysis]
11 Bentur L, Pollak M. Trikafta—Extending Its Success to Less Common Mutations. JPM 2022;12:1528. [DOI: 10.3390/jpm12091528] [Reference Citation Analysis]
12 Hillenaar T, Beekman J, van der Sluijs P, Braakman I. Redefining hypo- and hyper-responding phenotypes of CFTR mutants for understanding and therapy.. [DOI: 10.1101/2022.09.12.507537] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Li Pomi F, Di Bartolomeo L, Vaccaro M, Lentini M, Cristadoro S, Lucanto MC, Lombardo M, Costa S, Borgia F. Malassezia Folliculitis following Triple Therapy for Cystic Fibrosis. Medicina 2022;58:1204. [DOI: 10.3390/medicina58091204] [Reference Citation Analysis]
14 Cramer N, Nawrot ML, Wege L, Dorda M, Sommer C, Danov O, Wronski S, Braun A, Jonigk D, Fischer S, Munder A, Tümmler B. Competitive fitness of Pseudomonas aeruginosa isolates in human and murine precision-cut lung slices. Front Cell Infect Microbiol 2022;12:992214. [DOI: 10.3389/fcimb.2022.992214] [Reference Citation Analysis]
15 Despotes KA, Donaldson SH. Current state of CFTR modulators for treatment of Cystic Fibrosis. Current Opinion in Pharmacology 2022;65:102239. [DOI: 10.1016/j.coph.2022.102239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
16 Diseroad ER, Mogayzel PJ Jr, Pan A. Rechallenge of Elexacaftor/Tezacaftor/Ivacaftor After Skin Rash in Two Pediatric Patients. J Pediatr Pharmacol Ther 2022;27:463-6. [PMID: 35845562 DOI: 10.5863/1551-6776-27.5.463] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Loyd I, Papac N, Hirshburg J, Levin J, Dannelley J, Dorris J, Stratton J, Mehdi N. If At First You Don't Succeed, Trikafta Again. J Pediatr Pharmacol Ther 2022;27:467-9. [PMID: 35845559 DOI: 10.5863/1551-6776-27.5.467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Burgel P, Burnet E, Regard L, Martin C. The Changing Epidemiology of Cystic Fibrosis. Chest 2022. [DOI: 10.1016/j.chest.2022.07.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Regard L, Martin C, Burgel PR. Cystic Fibrosis in 2021: "The Times They Are A-Changin". Arch Bronconeumol 2022;58:536-8. [PMID: 35312571 DOI: 10.1016/j.arbres.2021.09.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Li Q, Liu S, Ma X, Yu J. Effectiveness and Safety of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Children With Cystic Fibrosis: A Meta-Analysis. Front Pediatr 2022;10:937250. [DOI: 10.3389/fped.2022.937250] [Reference Citation Analysis]
21 Moslemi A, Makimoto K, Tan WC, Bourbeau J, Hogg JC, Coxson HO, Kirby M; Canadian Cohort of Obstructive Lung Disease. Quantitative CT Lung Imaging and Machine Learning Improves Prediction of Emergency Room Visits and Hospitalizations in COPD. Acad Radiol 2022:S1076-6332(22)00311-7. [PMID: 35690537 DOI: 10.1016/j.acra.2022.05.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Mercier J, Foucaud P. Modulateurs pharmacologiques du canal CFTR : une révolution thérapeutique dans la mucoviscidose. Bulletin de l'Académie Nationale de Médecine 2022;206:775-786. [DOI: 10.1016/j.banm.2022.01.027] [Reference Citation Analysis]
23 Cholon DM, Gentzsch M. Established and novel human translational models to advance cystic fibrosis research, drug discovery, and optimize CFTR-targeting therapeutics. Current Opinion in Pharmacology 2022;64:102210. [DOI: 10.1016/j.coph.2022.102210] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Regard L, Martin C, Burnet E, Da Silva J, Burgel P. CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France. Cells 2022;11:1769. [DOI: 10.3390/cells11111769] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Centorame A, Dumut DC, Youssef M, Ondra M, Kianicka I, Shah J, Paun RA, Ozdian T, Hanrahan JW, Gusev E, Petrof B, Hajduch M, Pislariu R, De Sanctis JB, Radzioch D. Treatment With LAU-7b Complements CFTR Modulator Therapy by Improving Lung Physiology and Normalizing Lipid Imbalance Associated With CF Lung Disease. Front Pharmacol 2022;13:876842. [DOI: 10.3389/fphar.2022.876842] [Reference Citation Analysis]
26 King JA, Nichols A, Bentley S, Carr SB, Davies JC. An Update on CFTR Modulators as New Therapies for Cystic Fibrosis. Pediatr Drugs. [DOI: 10.1007/s40272-022-00509-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
27 Migliorisi G, Collura M, Ficili F, Pensabene T, Bongiorno D, Collura A, Di Bernardo F, Stefani S. Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study. Pharmaceuticals 2022;15:606. [DOI: 10.3390/ph15050606] [Reference Citation Analysis]
28 Manika K, Diamantea F. The new triple combination in CFTR modulators: A new era in the management of cystic fibrosis. Pneumon 2022;35:1-4. [DOI: 10.18332/pne/147170] [Reference Citation Analysis]
29 Costa E, Girotti S, Pauro F, Leufkens HGM, Cipolli M. The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis. Orphanet J Rare Dis 2022;17:188. [PMID: 35525974 DOI: 10.1186/s13023-022-02350-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Korten I, Kieninger E, Krueger L, Bullo M, Flück CE, Latzin P, Casaulta C, Boettcher C. Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis—An Observational Pilot Study. Front Pediatr 2022;10:852551. [DOI: 10.3389/fped.2022.852551] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Wang Y, Ma B, Li W, Li P. Efficacy and Safety of Triple Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Patients With Cystic Fibrosis: A Meta-Analysis of Randomized Controlled Trials. Front Pharmacol 2022;13:863280. [PMID: 35359862 DOI: 10.3389/fphar.2022.863280] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Barr HL, Bihouee T, Zwitserloot AM. A year in review: Real world evidence, functional monitoring and emerging therapeutics in 2021. J Cyst Fibros 2022:S1569-1993(22)00046-7. [PMID: 35272931 DOI: 10.1016/j.jcf.2022.02.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Mainz JG, Schwarz C, Jagdhuhn M, Kurzidim L, Eschenhagen P. Update zur Therapie der CF bei Kindern und Jugendlichen. Pneumologe 2022;19:104-110. [DOI: 10.1007/s10405-022-00436-2] [Reference Citation Analysis]
34 Sutharsan S, Mckone EF, Downey DG, Duckers J, Macgregor G, Tullis E, Van Braeckel E, Wainwright CE, Watson D, Ahluwalia N, Bruinsma BG, Harris C, Lam AP, Lou Y, Moskowitz SM, Tian S, Yuan J, Waltz D, Mall MA, Aurora P, Verhulst S, Watson D, Lorenz M, Roehmel J, Gleiber W, Naehrig S, Stehling F, Sutharsan S, van Koningsbruggen-rietschel S, Fischer R, Downey D, Haworth C, Duckers J, Legg J, Barry P, Thursfield R, Doe SJ, Hilliard T, Macgregor G, Nash EF, Withers NJ, Peckham D, Barr HL, Lee T, Gray R, Vermeulen F, Van Braeckel E, Vanderhelst E, Robinson PJ, Wainwright CE, Smith DJ, Mulrennan SA, Clements BS, Wark P. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. The Lancet Respiratory Medicine 2022;10:267-77. [DOI: 10.1016/s2213-2600(21)00454-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
35 Oestreich M, Wyler F, Etter B, Ramsey KA, Latzin P. A non-systematic signal-correction error in a commercial multiple-breath washout device significantly impacts outcomes in children and adults.. [DOI: 10.1101/2022.01.27.22269250] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Andrade A, Pizarro ME. Medicina de precisión en fibrosis quística. Revista Médica Clínica Las Condes 2022;33:44-50. [DOI: 10.1016/j.rmclc.2021.12.003] [Reference Citation Analysis]
37 Schwarz C, Eschenhagen P, Schütte H, Sparke C, Jagdhuhn M, Mainz J. Cystische Fibrose: Innovative Arzneimittel verlängern Lebenserwartung. Deutsches Ärzteblatt Online 2021. [DOI: 10.3238/perspneumo.2021.12.17.06] [Reference Citation Analysis]
38 Dumas MP, Xia S, Bear CE, Ratjen F. Perspectives on the translation of in-vitro studies to precision medicine in Cystic Fibrosis. EBioMedicine 2021;73:103660. [PMID: 34740114 DOI: 10.1016/j.ebiom.2021.103660] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Barry PJ, Taylor-Cousar JL. Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world - opportunities and challenges. Curr Opin Pulm Med 2021;27:554-66. [PMID: 34420018 DOI: 10.1097/MCP.0000000000000819] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
40 Pallenberg ST, Junge S, Ringshausen FC, Sauer-Heilborn A, Hansen G, Dittrich AM, Tümmler B, Nietert M. CFTR modulation with elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis assessed by the β-adrenergic sweat rate assay. J Cyst Fibros 2021:S1569-1993(21)02107-X. [PMID: 34756683 DOI: 10.1016/j.jcf.2021.10.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Meoli A, Fainardi V, Deolmi M, Chiopris G, Marinelli F, Caminiti C, Esposito S, Pisi G. State of the Art on Approved Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators and Triple-Combination Therapy. Pharmaceuticals (Basel) 2021;14:928. [PMID: 34577628 DOI: 10.3390/ph14090928] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
42 Robinson PD, Jensen R, Seeto RA, Stanojevic S, Saunders C, Short C, Davies JC, Ratjen F. Impact of cross-sensitivity error correction on representative nitrogen-based multiple breath washout data from clinical trials. J Cyst Fibros 2021:S1569-1993(21)01374-6. [PMID: 34526221 DOI: 10.1016/j.jcf.2021.08.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
43 Anderson A, McCoy L, Pettit RS, Wright BA, Lubsch L. Early insurance coverage of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis. Pediatr Pulmonol 2021;56:4053-4. [PMID: 34499822 DOI: 10.1002/ppul.25659] [Reference Citation Analysis]
44 Karb DB, Cummings LC. The Intestinal Microbiome and Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Emerging Themes in the Management of Gastrointestinal Manifestations of Cystic Fibrosis. Curr Gastroenterol Rep 2021;23:17. [PMID: 34448955 DOI: 10.1007/s11894-021-00817-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Zaher A, ElSaygh J, Elsori D, ElSaygh H, Sanni A. A Review of Trikafta: Triple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy. Cureus 2021;13:e16144. [PMID: 34268058 DOI: 10.7759/cureus.16144] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
46 Bergeron C, Cantin AM. New Therapies to Correct the Cystic Fibrosis Basic Defect. Int J Mol Sci 2021;22:6193. [PMID: 34201249 DOI: 10.3390/ijms22126193] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
47 Graeber SY, Vitzthum C, Mall MA. Potential of Intestinal Current Measurement for Personalized Treatment of Patients with Cystic Fibrosis. J Pers Med 2021;11:384. [PMID: 34066648 DOI: 10.3390/jpm11050384] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]